Introduction
Material and methods
Details of ethics approval
Settings
Inclusion and exclusion criteria
ICD-10 | Before exclusions (N = 7,795) | After exclusions (N = 2,311) |
---|---|---|
I676 | 119 (2 %) | 27 (1 %) |
I80 | 4,545 (58 %) | 1,156 (50 %) |
I81 | 76 (1 %) | 20 (1 %) |
I82 | 1,143 (15 %) | 358 (15 %) |
I26 | 1,887 (24 %) | 746 (32 %) |
Cases | Controls | |
---|---|---|
Start | 7,795 | 2,495,994 |
(1) Antithrombotic agent within 14 days | 2,964 | - |
(2) Father and mother were not registered in the Multi-Generation Register | 971 | 404,747 |
(3) Individuals with previously registered diagnoses of any type of VTE | 1,560 | 15,334 |
(4) Hysterectomy | 240 | 17,362 |
(4) Bilateral oophorectomy/Unilateral oophorectomy twice | 75 | 3,817 |
(4) Sterilization | 242 | 29.331 |
(4) Coronary heart disease/Heart failure/Cerebrovascular disease | 191 | 6,915 |
(5) Cancer | 373 | 8,957 |
(6) Infertility | 240 | 37,239 |
(7) Pregnancy | 343 | 56,043 |
(8) Women who stopped use of any contraceptives prior to the VTE diagnosis | 982 | 312,099 |
Unable to match with 5 controls | 98 | - |
Included in the analysis | 2,311 | 11,555 |
Statistical analysis
Results
CASES | CONTROLSa
| |||||
---|---|---|---|---|---|---|
Contraceptives | Contraceptives | |||||
No | Yes | All | No | Yes | All | |
Age (years)b
| 36.4 (9.5)a
| |||||
No VTE in relative | 1,395 (72.9) | 520 (27.2) | 1,915 (82.9) | 9,013 (85.5) | 1,535 (14.6) | 10,548 (91.3) |
VTE in relative | 361 (91.2) | 35 (8.8) | 396 (17.1) | 962 (95.5) | 45 (4.5) | 1,007 (8.7) |
1,756 (76.0) | 555 (24.0) | 2,311 | 9,975 (86.3) | 1,580 (13.7) | 11,555 |
Risk of VTE in COC users and women with a family history of VTE
Model A1 and A2 | Model B | Model C | |
---|---|---|---|
Odds ratio | Odds ratio | Odds ratio | |
Contraceptives | 2.40 (2.12-2.72)a
| 2.53 (2.23-2.87) | 2.54 (2.23-2.90) |
VTE in relative | 2.23 (1.96-2.53)b
| 2.38 (2.09-2.71) | 2.39 (2.09-2.74) |
VTE in relative *Contraceptives | 0.92 (0.57-1.46) |
Beta (SE) | |
---|---|
Contraceptives | 0.12 (0.009) |
VTE in relative | 0.14 (0.011) |
Interaction between VTE in relative and Contraceptives | 0.05 (0.043)a
|
Different generations of COCs
OR (95 % CI) | Estimated OR | |
---|---|---|
Generation 1 | Ref | 2.00 (1.44-2.79) |
Generation 2 | 1.04 (0.74-1.48) | 2.09 (1.29-3.37)a
|
Generation 3 | 1.23 (0.84-1.80) | 2.46 (1.48-4.09)a
|
Generation 4 | 1.79 (1.22-2.62) | 3.58 (2.16-5.93)a
|
Undefined generation | 1.64 (0.52-5.15) | 3.29 (1.00-10.82)a
|
New users of COC
OR (95 % CI) | Estimated OR | |
---|---|---|
Contraceptives | 2.12 (1.84-2.44) | |
Users of COC for more than 6 months | Ref | 2.12 (1.84-2.44) |
New Users of COC | 1.67 (1.33-2.09)a
| 3.53 (2.56-4.36) |
Age and COC use
OR (95 % CI) | |
---|---|
Contraceptives | 2.40 (2.08-2.76) |
Interaction between COC use with age | 1.00 (0.99-1.01) |
Sensitivity analysis
Model A1 and A2 | Model B | Model C | |
---|---|---|---|
Odds ratio | Odds ratio | Odds ratio | |
Contraceptives | 1.92 (1.76-2.10) | 2.00 (1.82-2.18) | 1.97 (1.80-2.16) |
VTE in relative | 2.42 (2.24-2.60) | 2.47 (2.29-2.66) | 2.45 (2.27-2.64) |
VTE in relative *Contraceptives | 1.23 (0.84-1.82) |